tetano
Editor, Senior Moderator
Vaccine. 2011 Jun 17. [Epub ahead of print]
Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects.
Yanagisawa N, Kazuhiro M, Ajisawa A, Imamura A, Suganuma A, Ando M, Takayama N, Okuno Y.
Source
Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Japan.
Abstract
We evaluated the immunogenicity and safety of the influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. A total of 182 HIV-infected and 42 HIV-uninfected subjects were enrolled, and antibody (ab) titers were measured by hemagglutination-inhibition assay at baseline and 32.3?10.4 and 29.7?3.3 days after vaccination, respectively. In the HIV-infected cohort, ab titers ≥1:40 at baseline and post-vaccination were 12.6% and 49.5%, respectively. The seroconversion rate, defined as either an ab titer ≤1:10 before and ≥1:40 after or ≥1:10 before and ≥4-fold increase in ab titer, was only 38.5% in the HIV-infected cohort, whereas the rate was 85.7% in the HIV-uninfected cohort. Multivariate logistic regression analysis showed that the CD4 cell count was the only significant predictor of a positive vaccine response. There were no serious adverse events in any of the subjects receiving the vaccine. Additional study is warranted to identify a more effective method of vaccinating HIV-infected Japanese subjects.
Copyright ? 2011. Published by Elsevier Ltd.
PMID:
21689709
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21689709
Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects.
Yanagisawa N, Kazuhiro M, Ajisawa A, Imamura A, Suganuma A, Ando M, Takayama N, Okuno Y.
Source
Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Japan.
Abstract
We evaluated the immunogenicity and safety of the influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. A total of 182 HIV-infected and 42 HIV-uninfected subjects were enrolled, and antibody (ab) titers were measured by hemagglutination-inhibition assay at baseline and 32.3?10.4 and 29.7?3.3 days after vaccination, respectively. In the HIV-infected cohort, ab titers ≥1:40 at baseline and post-vaccination were 12.6% and 49.5%, respectively. The seroconversion rate, defined as either an ab titer ≤1:10 before and ≥1:40 after or ≥1:10 before and ≥4-fold increase in ab titer, was only 38.5% in the HIV-infected cohort, whereas the rate was 85.7% in the HIV-uninfected cohort. Multivariate logistic regression analysis showed that the CD4 cell count was the only significant predictor of a positive vaccine response. There were no serious adverse events in any of the subjects receiving the vaccine. Additional study is warranted to identify a more effective method of vaccinating HIV-infected Japanese subjects.
Copyright ? 2011. Published by Elsevier Ltd.
PMID:
21689709
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21689709